Literature DB >> 21263320

Preclinical evaluation of epinephrine nebulization to reduce airway hyperemia and improve oxygenation after smoke inhalation injury.

Matthias Lange1, Atsumori Hamahata, Daniel L Traber, Robert A Cox, Gabriela A Kulp, Yoshimitsu Nakano, Lillian D Traber, David N Herndon, Perenlei Enkhbaatar.   

Abstract

OBJECTIVE: Acute lung injury secondary to smoke inhalation is a major source of morbidity and mortality in burn patients. We tested the hypothesis that nebulized epinephrine would ameliorate pulmonary dysfunction secondary to acute lung injury by reducing airway hyperemia and edema formation and mediating bronchodilatation in an established, large animal model of inhalation injury.
DESIGN: Prospective, controlled, randomized trial.
SETTING: University research laboratory.
SUBJECTS: Twenty-four chronically instrumented, adult, female sheep.
INTERVENTIONS: Following baseline measurements, the animals were allocated to a sham-injured group (n = 5), an injured and saline-treated group (n = 6), or an injured group treated with 4 mg of nebulized epinephrine every 4 hrs (n = 6). Inhalation injury was induced by 48 breaths of cotton smoke. The dose of epinephrine was derived from dose finding experiments (n = 7 sheep).
MEASUREMENTS AND MAIN RESULTS: The injury induced significant increases in airway blood flows, bronchial wet/dry weight ratio, airway obstruction scores, ventilatory pressures, and lung malondialdehyde content, and contributed to severe pulmonary dysfunction as evidenced by a significant decline in Pao₂/Fio₂ ratio and increase in pulmonary shunt fraction. Nebulization of epinephrine significantly reduced tracheal and main bronchial blood flows, ventilatory pressures, and lung malondialdehyde content. The treatment was further associated with significant improvements of Pao₂/FIO₂ ratio and pulmonary shunting.
CONCLUSIONS: Nebulization of epinephrine reduces airway blood flow and attenuates pulmonary dysfunction in sheep subjected to severe smoke inhalation injury. Future studies will have to improve the understanding of the underlying pathomechanisms and identify the optimal dosing for the treatment of patients with this injury.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21263320      PMCID: PMC3845036          DOI: 10.1097/CCM.0b013e318207ec52

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  25 in total

Review 1.  Pharmacological regulation of the neuronal control of airway mucus secretion.

Authors:  Duncan F Rogers
Journal:  Curr Opin Pharmacol       Date:  2002-06       Impact factor: 5.547

2.  Airway hyperresponsiveness to bronchoconstrictor challenge after wood smoke exposure in guinea pigs.

Authors:  T H Hsu; Y R Kou
Journal:  Life Sci       Date:  2001-05-18       Impact factor: 5.037

3.  Effect of poly(ADP ribose) synthetase inhibition on burn and smoke inhalation injury in sheep.

Authors:  Katsumi Shimoda; Kazunori Murakami; Perenlei Enkhbaatar; Lillian D Traber; Robert A Cox; Hal K Hawkins; Frank C Schmalstieg; Katalin Komjati; Jon G Mabley; Csaba Szabo; Andrew L Salzman; Daniel L Traber
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-03-07       Impact factor: 5.464

4.  Reversal of catabolism by beta-blockade after severe burns.

Authors:  D N Herndon; D W Hart; S E Wolf; D L Chinkes; R R Wolfe
Journal:  N Engl J Med       Date:  2001-10-25       Impact factor: 91.245

5.  The inducible nitric oxide synthase inhibitor BBS-2 prevents acute lung injury in sheep after burn and smoke inhalation injury.

Authors:  Perenlei Enkhbaatar; Kazunori Murakami; Katsumi Shimoda; Akio Mizutani; Lillian Traber; Gary B Phillips; John F Parkinson; Robert Cox; Hal Hawkins; David Herndon; Daniel Traber
Journal:  Am J Respir Crit Care Med       Date:  2003-04-01       Impact factor: 21.405

6.  Airway obstruction in sheep with burn and smoke inhalation injuries.

Authors:  Robert A Cox; Ann S Burke; Kazutaka Soejima; Kazunori Murakami; Jiro Katahira; Lillian D Traber; David N Herndon; Frank C Schmalstieg; Daniel L Traber; Hal K Hawkins
Journal:  Am J Respir Cell Mol Biol       Date:  2003-09       Impact factor: 6.914

Review 7.  The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders.

Authors:  P O Hassa; M O Hottiger
Journal:  Cell Mol Life Sci       Date:  2002-09       Impact factor: 9.261

8.  Aerosolized tissue plasminogen inhibitor improves pulmonary function in sheep with burn and smoke inhalation.

Authors:  Perenlei Enkhbaatar; Kazunori Murakami; Robert Cox; Martin Westphal; Naoki Morita; Kimberly Brantley; Ann Burke; Hal Hawkins; Frank Schmalstieg; Lillian Traber; David Herndon; Daniel Traber
Journal:  Shock       Date:  2004-07       Impact factor: 3.454

9.  Upper airway mucus deposition in lung tissue of burn trauma victims.

Authors:  Robert A Cox; Ron P Mlcak; David L Chinkes; Sam Jacob; Perenlei Enkhbaatar; Jesse Jaso; Lauren P Parish; Daniel L Traber; Marc G Jeschke; David N Herndon; Hal K Hawkins
Journal:  Shock       Date:  2008-03       Impact factor: 3.454

10.  Burn size determines the inflammatory and hypermetabolic response.

Authors:  Marc G Jeschke; Ronald P Mlcak; Celeste C Finnerty; William B Norbury; Gerd G Gauglitz; Gabriela A Kulp; David N Herndon
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more
  12 in total

1.  Time profile of oxidative stress and neutrophil activation in ovine acute lung injury and sepsis.

Authors:  Matthias Lange; Csaba Szabo; Daniel L Traber; Eszter Horvath; Atsumori Hamahata; Yoshimitsu Nakano; Lillian D Traber; Robert A Cox; Frank C Schmalstieg; David N Herndon; Perenlei Enkhbaatar
Journal:  Shock       Date:  2012-05       Impact factor: 3.454

Review 2.  Inhalation Injury in the Burned Patient.

Authors:  Guillermo Foncerrada; Derek M Culnan; Karel D Capek; Sagrario González-Trejo; Janos Cambiaso-Daniel; Lee C Woodson; David N Herndon; Celeste C Finnerty; Jong O Lee
Journal:  Ann Plast Surg       Date:  2018-03       Impact factor: 1.539

Review 3.  [Sleeve lobectomy: perioperative risks and functional results].

Authors:  T P Graeter
Journal:  Chirurg       Date:  2013-06       Impact factor: 0.955

4.  Safety of Nebulized Epinephrine in Smoke Inhalation Injury.

Authors:  Guillermo Foncerrada; Francisco Lima; Robert P Clayton; Ronald P Mlcak; Perenlei Enkhbaatar; David N Herndon; Oscar E Suman
Journal:  J Burn Care Res       Date:  2017 Nov/Dec       Impact factor: 1.845

Review 5.  Inhalation Injury: Pathophysiology, Diagnosis, and Treatment.

Authors:  Samuel W Jones; Felicia N Williams; Bruce A Cairns; Robert Cartotto
Journal:  Clin Plast Surg       Date:  2017-04-18       Impact factor: 2.017

6.  Arginine vasopressin receptor 2 activation promotes microvascular permeability in sepsis.

Authors:  Ernesto Lopez; Satoshi Fukuda; Katalin Modis; Osamu Fujiwara; Baigal Enkhtaivan; Raul Trujillo-Abarca; Koji Ihara; Francisco Lima-Lopez; Dannelys Perez-Bello; Csaba Szabo; Donald S Prough; Perenlei Enkhbaatar
Journal:  Pharmacol Res       Date:  2020-11-04       Impact factor: 7.658

7.  Evidence of altered haemostasis in an ovine model of venovenous extracorporeal membrane oxygenation support.

Authors:  Margaret R Passmore; Yoke L Fung; Gabriela Simonova; Samuel R Foley; Sara D Diab; Kimble R Dunster; Michelle M Spanevello; Charles I McDonald; John-Paul Tung; Natalie M Pecheniuk; Karen Hay; Kiran Shekar; John F Fraser
Journal:  Crit Care       Date:  2017-07-29       Impact factor: 9.097

Review 8.  Inhalation injury: epidemiology, pathology, treatment strategies.

Authors:  David J Dries; Frederick W Endorf
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2013-04-19       Impact factor: 2.953

Review 9.  Assessing inhalation injury in the emergency room.

Authors:  Shinsuke Tanizaki
Journal:  Open Access Emerg Med       Date:  2015-07-20

Review 10.  Diagnosis and management of inhalation injury: an updated review.

Authors:  Patrick F Walker; Michelle F Buehner; Leslie A Wood; Nathan L Boyer; Ian R Driscoll; Jonathan B Lundy; Leopoldo C Cancio; Kevin K Chung
Journal:  Crit Care       Date:  2015-10-28       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.